Pages that link to "Q46651029"
Jump to navigation
Jump to search
The following pages link to Treatment arms summarizing analysis of 220 high-grade glioma studies (Q46651029):
Displaying 7 items.
- Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials (Q33586021) (← links)
- Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis (Q33594928) (← links)
- Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies (Q37141964) (← links)
- Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients (Q44941609) (← links)
- Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients (Q46769502) (← links)
- Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma (Q47436703) (← links)
- Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. (Q52585817) (← links)